Haleon: share rises on 'solid' results

(CercleFinance.com) - On Thursday, consumer healthcare products manufacturer Haleon reported solid 2023 results, boosting its share price.


The British group announced this morning that it generated sales up 4.1% to £11.3bn last year, including organic growth of 8%.

In a reaction note, analysts at UBS point out that the owner of the Advil, Sensodyne, Voltaren and Polident brands recorded organic growth of 6.7% in Q4, against a consensus of 5%.

Above all, this better-than-expected performance can be attributed both to good volumes and mix (+0.3% vs. a consensus of -0.2%), and to prices (+6.4% vs. +5.5% expected), the broker notes.

For 2024, Haleon anticipates "another year of strong growth", with organic growth expected to be between 4% and 6%.

The company also plans to allocate £500m to share buy-backs over the year.

Following these announcements, the share price climbed over 6% on the London Stock Exchange on Thursday morning, making it one of the biggest risers on the pan-European STOXX 600 index.


Copyright (c) 2024 CercleFinance.com. All rights reserved.